BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $4523.T readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06602258-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:E2814 readout (P2) · Eisai Inc. $4523.T
DESCRIPTION:A Study of E2814 With Concurrent Lecanemab Treatment in Partici
 pants With Early Alzheimer's Disease\n\nPrimary completion date: 2026-12-0
 3 (estimated)\nOriginally planned: 2026-06-04 (+6.0 months)\nPhase 2 · Ne
 uro · Alzheimer's Disease\nEnrollment: 105 · Sites: 26\n\nPrimary comple
 tion = last participant's primary-endpoint data collected\; topline result
 s usually follow weeks to months later. Sponsor-reported\, often an estima
 te. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nc
 t=NCT06602258\nhttps://clinicaltrials.gov/study/NCT06602258
URL:https://datacutoff.com/radar.html?nct=NCT06602258
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03887455-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Clarity AD readout (P3) · Eisai Inc. $4523.T
DESCRIPTION:A Study to Confirm Safety and Efficacy of Lecanemab in Particip
 ants With Early Alzheimer's Disease\n\nPrimary completion date: 2026-12-31
  (estimated)\nOriginally planned: 2024-03-07 (+33.8 months)\nPhase 3 · Ne
 uro · Early Alzheimer's Disease\nEnrollment: 1906 · Sites: 247\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT03887455\nhttps://clinicaltrials.gov/study/NCT03887455
URL:https://datacutoff.com/radar.html?nct=NCT03887455
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493265-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:E2086 readout (P2) · Eisai Inc. $4523.T
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of E2086 in Adults 
 With Narcolepsy\n\nPrimary completion date: 2027-02-14 (estimated)\nPhase 
 2 · Neuro · Narcolepsy\nEnrollment: 64 · Sites: 57\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=N
 CT07493265\nhttps://clinicaltrials.gov/study/NCT07493265
URL:https://datacutoff.com/radar.html?nct=NCT07493265
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04015141-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Perampanel Oral Suspension readout (P2) · Eisai Inc. $4523.T
DESCRIPTION:A Study to Evaluate Efficacy and Safety of Perampanel Administe
 red as an Adjunctive Therapy in Pediatric Participants With Childhood Epil
 epsy\n\nPrimary completion date: 2027-04-06 (estimated)\nOriginally planne
 d: 2021-10-13 (+65.7 months)\nPhase 2 · Neuro · Pediatric Epileptic Synd
 rome\, Partial-onset Seizures\nEnrollment: 100 · Sites: 35\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT04015141\nhttps://clinicaltrials.gov/study/NCT04015141
URL:https://datacutoff.com/radar.html?nct=NCT04015141
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
